View Older Stories View More Recent Stories

Jul 29, 2019 04:05PM Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia
Jul 29, 2019 06:56AM Merck (MRK) in Combination with Chemotherapy Met Primary Endpoint of pCR in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with TNBC
Jul 29, 2019 06:55AM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative
Jul 29, 2019 06:31AM Merck (MRK) Announces EMA Adopts Positive Opinion for KEYTRUDA in Combination with Inlyta as First-Line Treatment for Advanced RCC
Jul 29, 2019 06:30AM European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
Jul 24, 2019 11:03AM Merck (MRK) Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir at IAS
Jul 24, 2019 11:00AM Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019
Jul 23, 2019 12:54PM Merck Announces Fourth-Quarter 2019 Dividend
Jul 23, 2019 11:01AM Merck (MRK) Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir
Jul 23, 2019 11:00AM Merck Presents Early Evidence on Extended Delivery of Investigational Anti-HIV-1 Agent Islatravir (MK-8591) via Subdermal Implant
Jul 23, 2019 06:48AM Merck (MRK), Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA plus LENVIMA Combination Treatment
Jul 23, 2019 06:45AM Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment
Jul 22, 2019 04:30PM Sure Petcare Launches SureFeed® Microchip Pet Feeder Connect
Jul 18, 2019 08:00AM MilliporeSigma and Broad Institute Announce CRISPR License Framework to Encourage Innovation
Jul 17, 2019 06:48AM Merck (MRK) Announces FDA Approves its RECARBRIO for Treatment of Adults with cUTI and Complicated Intra-Abdominal Bacterial Infections
Jul 17, 2019 06:45AM FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited
Jul 10, 2019 06:45AM Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019
Jul 9, 2019 06:46AM Merck (MRK) Announces FDA Accepts its sBLA for KEYTRUDA Six-Week Dosing Schedule for Melanoma and Multiple Other Indications
Jul 9, 2019 06:45AM FDA Accepts Merck’s Supplemental Biologics License Applications for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule for Melanoma and Multiple Other Indications
Jul 1, 2019 06:45AM Merck to Hold Second-Quarter 2019 Sales and Earnings Conference Call on July 30
Jun 26, 2019 04:58PM Merck (MRK) Announces CDC ACIP Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27-45 with GARDASIL9 & Harmonization of Catch-up Vaccination
Jun 26, 2019 04:45PM CDC Advisory Committee on Immunization Practices (ACIP) Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27-45 with GARDASIL®9 & Harmonization of Ca
Jun 20, 2019 01:30PM Massachusetts-based Business Sectors of Merck KGaA, Darmstadt, Germany Named 'Best Places to Work' by Boston Business Journal
Jun 20, 2019 06:54AM Merck (MRK) Outlines Business Momentum, Strong Expected Growth
Jun 20, 2019 06:45AM Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
Jun 19, 2019 06:48AM AstraZeneca (AZN) and Merck's LYNPARZA Approved in Japan as First-Line Maintenance Therapy in Patients with BRCAm Advanced Ovarian Cancer
Jun 19, 2019 06:45AM AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
Jun 18, 2019 06:47AM Merck (MRK) Announces FDA Approved its KEYTRUDA as Monotherapy for Some Patients with Metastatic SCLC with Disease Progression
Jun 18, 2019 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Leas
Jun 18, 2019 06:30AM LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
Jun 13, 2019 08:14AM IBM (IBM), Merck (MRK), Walmart (WMT), KPMG to Collaborate with FDA on Pharma Product Integrity Protection Using Blockchain
Jun 13, 2019 08:05AM IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of blockchain to protect pharmaceutical product integrity
Jun 11, 2019 06:46AM Merck (MRK) Announces FDA Approved Two New Indications for KEYTRUDA
Jun 11, 2019 06:45AM FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
Jun 10, 2019 06:45AM Merck (MRK) to Acquire Tilos Therapeutics for up to $773 Million
Jun 10, 2019 06:45AM Merck to Acquire Tilos Therapeutics
Jun 3, 2019 04:57PM Merck (MRK) Confirms FDA Approved its ZERBAXA 3g Dose for Treatment of Adults with HABP/VABP
Jun 3, 2019 04:55PM FDA Approves Merck’s ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Jun 3, 2019 04:19PM Merck's (MRK) LYNPARZA Phase 3 SOLO3 Trial Demonstrated 72% OR Rate in Patients with Platinum-Sensitive Relapsed gBRCAm
Jun 3, 2019 04:15PM LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patie
Jun 3, 2019 06:04AM Merck (MRK), AstraZeneca (AZN) Report Results from Phase 3 POLO trial evaluating LYNPARZA as First-Line Maintenance Therapy
Jun 2, 2019 07:30AM LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Ca
Jun 1, 2019 07:30AM Five-Year Survival Data for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting
May 31, 2019 06:48AM Merck's (MRK) KEYTRUDA (pembrolizumab) Demonstrates Improved OS at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial
May 31, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase
May 28, 2019 04:05PM Merck Announces Third-Quarter 2019 Dividend
May 21, 2019 06:50AM Merck (MRK) to Acquire Peloton Therapeutics for $1.05 Billion Upfront, Plus $1.15 Billion Contingent
May 21, 2019 06:45AM Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
May 20, 2019 04:32PM Merck (MRK) Phase 3 KEYNOTE-119 Study of KEYTRUDA Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer Doesn't Meet Primary Endpoint
May 20, 2019 04:30PM Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer
View More Recent Stories View Older Stories